New Jersey runs one of the more aggressive AG-led consumer protection programs in the country, and the State Board of Medical Examiners has detailed advertising rules that pair with that authority.
State-level overview
New Jersey healthcare marketing operates under the State Board of Medical Examiners (BME), which enforces N.J.A.C. 13:35-6.10 - one of the more prescriptive state physician advertising rules in the country. The AG's Division of Consumer Affairs runs an active consumer protection program under the New Jersey Consumer Fraud Act (CFA), and healthcare marketing is a recurring focus, particularly in cosmetic surgery, weight loss, and telehealth contexts.
The BME enforces N.J.A.C. 13:35-6.10, which has specific provisions covering deceptive advertising, before/after photo disclosure, testimonial handling, guarantee restrictions, and 'board-certified' language. New Jersey also has unusually clear rules on how cosmetic and aesthetic specialties may be claimed and what constitutes a fee-disclosure violation in advertised pricing.
The NJ AG (through Division of Consumer Affairs) uses the Consumer Fraud Act, which provides treble damages and attorney fees - making private CFA actions a meaningful additional risk vector beyond AG enforcement. Recent enforcement has included cosmetic surgery package pricing, telehealth weight-loss marketing, and medical-spa supervision representations.
Enforcement focus
N.J.A.C. 13:35-6.10 has specific fee-disclosure requirements when prices are advertised. New Jersey AG has pursued cosmetic practices for inadequate disclosure of additional charges (anesthesia, facility fees, post-op care) in advertised package pricing.
BME requires specific certifying-board disclosure and only recognizes ABMS or BME-approved equivalents. Use of non-recognized board certifications without qualification has been a recurring disciplinary basis.
BME enforces supervision requirements for non-physician injectors. Marketing language implying nurse-injector independence is treated as supervision misrepresentation.
CFA permits private suits with treble damages and fees, creating exposure to class actions in addition to AG action.
Patterns we flag in New Jersey
Package pricing without explicit add-on disclosure
Why: BME and CFA both have direct authority on inadequate fee disclosure.
'Board-certified' without ABMS-or-equivalent qualifier
Why: BME enforces specific board-certification disclosure rules.
Nurse-injector independence language
Why: BME treats implied independence as supervision misrepresentation.
Outcome guarantees in cosmetic or weight-loss marketing
Why: Both BME advertising rules and CFA private-action exposure apply.
Before/after photos without typical-experience disclosure
Why: N.J.A.C. 13:35-6.10 has specific before/after disclosure provisions.
By specialty
By specialty in New Jersey
Specialty rules stack on top of state rules. Find the specialty-specific framework that applies to your practice.
Disclaimer
This summary reflects general patterns in New Jersey healthcare marketing enforcement; it is not legal advice. For state-specific guidance on your practice, consult a New Jersey-licensed healthcare marketing attorney.
RegenCompliance applies federal FDA and FTC rules plus the most-enforced state patterns automatically. New Jersey-specific language is part of the rule set.
Other state guides
See allCalifornia healthcare marketing sits under the strictest state-level enforcement environment in the country - Medical Board of California rules, Business & Professions Code §17500 false advertising authority, and active AG consumer protection.
Read state guideTexas has an active Medical Board with specific rules for medical advertising, and the DTPA gives consumers and the state AG independent enforcement authority over deceptive healthcare marketing.
Read state guideFlorida's regulatory environment is defined by the Board of Medicine, FDUTPA, and an AG office that has been active on healthcare marketing - particularly in the fast-growing med spa, weight-loss, and regen categories.
Read state guide